Radiomics and molecular analysis: Bridging the gap for predicting hepatocellular carcinoma prognosis.

Abstract

This editorial examines a recent study that used radiomics based on computed tomography (CT) to predict the expression of the fibroblast-related gene enhancer of zeste homolog 2 (EZH2) and its correlation with the survival of patients with hepatocellular carcinoma (HCC). By integrating radiomics with molecular analysis, the study presented a strategy for accurately predicting the expression of EZH2 from CT scans. The findings demonstrated a strong link between the radiomics model, EZH2 expression, and patient prognosis. This noninvasive approach provides valuable insights into the therapeutic management of HCC.